A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- Moderate Chronic Plaque PsoriasisSevere Chronic Plaque PsoriasisMixed Guttate/Plaque Psoriasis
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 150
- Registration Number
- NCT04123795
- Locations
- 🇺🇸
Ps0007 50214, Auburn, Alabama, United States
🇺🇸Ps0007 50175, Phoenix, Arizona, United States
🇺🇸Ps0007 50213, Anaheim, California, United States
A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 214
- Registration Number
- NCT04109976
- Locations
- 🇵🇱
Dv0004 40097, Warsaw, Poland
🇺🇸Dv0004 50125, Charlotte, North Carolina, United States
🇺🇸Dv0004 50024, Boise, Idaho, United States
A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice
- First Posted Date
- 2019-08-13
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 412
- Registration Number
- NCT04053881
- Locations
- 🇩🇪
Ps0026 529, Gladbeck, Germany
🇩🇪Ps0026 518, Karlsruhe, Germany
🇩🇪Ps0026 532, Bogen, Germany
A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Interventions
- First Posted Date
- 2019-08-09
- Last Posted Date
- 2022-11-03
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 21
- Registration Number
- NCT04051944
- Locations
- 🇺🇸
Cidp04 50080, Durham, North Carolina, United States
🇺🇸Cidp04 50075, Augusta, Georgia, United States
🇬🇧Cidp04 40167, Sheffield, United Kingdom
A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 1131
- Registration Number
- NCT04009499
- Locations
- 🇺🇸
Pa0012 50017, Phoenix, Arizona, United States
🇺🇸Pa0012 50035, San Diego, California, United States
🇺🇸Pa0012 50033, Palm Harbor, Florida, United States
A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome
- Conditions
- Restless Legs Syndrome
- Interventions
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 10
- Registration Number
- NCT03992196
- Locations
- 🇺🇸
Rl0007 101, Culver City, California, United States
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Other: Placebo
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 200
- Registration Number
- NCT03971422
- Locations
- 🇺🇸
Mg0003 50092, Orange, California, United States
🇺🇸Mg0003 50105, Saint Louis, Missouri, United States
🇮🇹Mg0003 40149, Lazio, Italy
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis
- Conditions
- Nonradiographic Axial Spondyloarthritis
- Interventions
- Other: Placebo
- First Posted Date
- 2019-04-26
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 274
- Registration Number
- NCT03928704
- Locations
- 🇧🇪
As0010 40004, Bruxelles, Belgium
🇺🇸As0010 50060, Upland, California, United States
🇺🇸As0010 50016, Saint Louis, Missouri, United States
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis
- First Posted Date
- 2019-04-26
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 332
- Registration Number
- NCT03928743
- Locations
- 🇫🇷
As0011 40018, Boulogne Billancourt, France
🇯🇵As0011 20032, Suita, Japan
🇵🇱As0011 40039, Wroclaw, Poland
A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 400
- Registration Number
- NCT03896581
- Locations
- 🇺🇸
Pa0011 50004, Tustin, California, United States
🇺🇸Pa0011 50035, San Diego, California, United States
🇺🇸Pa0011 50017, Phoenix, Arizona, United States